ProTrials Research INC and Calithera Biosciences, Inc. have entered an agreement to further develop treatments for cancer.

According to the agreement, ProTrials Research will be responsible to provide a clinical trial developmental programme for Calithera Biosciences’ first-in-class inhibitor product CB-839 to target glutaminase enzyme in tumour metabolism.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Bristol-Myers Squibb has entered a clinical research agreement with Janssen Biotech, Inc. to evaluate the combination of the former’s immune-Oncology (I-O) agent Opdivo (nivolumab) and the latter’s Live Attenuated Double-Deleted (LADD),  listerial monocytogenes cancer immunotherapy expressing mesothelin and EGFRvIII (JNJ-64041757) in patients with non-small-cell lung cancer (NSCLC).

According to the agreement, the phase II clinical trial to evaluate the tolerability and clinical activity of the combination of two immune oncology compounds will be conducted by Janssen Biotech.

Espada Dermatology has acquired the GlyDerm line of skin care products from Lautus Pharmaceuticals LLC, allowing the company to offer GlyDerm skincare products.

Lumosa Therapeutics plans to raise gross proceeds of $14.53m through the public offering of 8.5 million of its common stock shares.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“ProTrials Research INC and Calithera Biosciences, Inc. have entered an agreement to further develop treatments for cancer.”

The company plans to use the funds to increase the working capital and enrich the operating funds.

Tricida INC has raised gross proceeds of $55m in a series C financing round.

The financing round was led by Longitute Capital Management Co LLC along with Vivo Capital LLC, Orbimed Advisors LLC, Sibling Capital Ventures and Limulus Ventures Partners LP, and SidleyAustin LLP acted as legal advisor to the offering.

The company plans to use the funds to conduct late-stage trials of the clinical candidate TRC101 in patients with kidney disease.

Image: Bristol-Myers Squibb has entered a clinical research agreement with Janssen Biotech. Photo: Courtesy of Bic.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact